1.19

1.71% 0.02

After Hours: 1.17 -0.02 -1.68%

Phio Pharmaceuticals Corp (PHIO)

Overview News Price History Financials Why PHIO Down? Discussions Forecast Stock Split

Phio Pharmaceuticals Corp stock is traded at $1.19, with a volume of 270.05K. It is up +1.71% in the last 24 hours and up +14.42% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Previous Close:

$1.17

Open:

$1.14

24h Volume:

270.05K

Relative Volume:

0.47

Market Cap:

$13.82M

Revenue:

Net Income/Loss:

$-10.93M

P/E Ratio:

-0.8277

EPS:

-1.4378

Net Cash Flow:

$-10.72M

1W Performance:

+13.33%

1M Performance:

+14.42%

6M Performance:

+13.33%

1Y Performance:

-40.20%

1-Day Range:

$1.14

$1.22

1-Week Range:

$1.08

$1.24

52-Week Range:

$0.8127

$4.1899

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name

Phio Pharmaceuticals Corp

Sector

Healthcare (1081)

Industry

Biotechnology (607)

Phone

(508) 767-3861

Address

411 SWEDELAND ROAD, KING OF PRUSSIA, MA

Employee

Twitter

@phio_pharma

Next Earnings Date

2026-08-13

Latest SEC Filings

PHIO's Discussions on Twitter

Compare PHIO vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHIO Phio Pharmaceuticals Corp	1.19	14.06M	0	-10.93M	-10.72M	-1.4378
VRTX Vertex Pharmaceuticals Inc	552.85	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	833.56	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,019.49	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	158.83	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.38	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-05-20	Initiated	H.C. Wainwright	Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

Aug 20, 2026

Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com

Aug 20, 2026

Phio Pharmaceuticals director Plott buys $17,100 in shares By Investing.com - Investing.com Canada

Aug 20, 2026

Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares - Stock Titan

Aug 20, 2026

Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView

Aug 20, 2026

Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00 - GuruFocus

Aug 20, 2026

Aug 19, 2026

Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan

Aug 19, 2026

Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView

Aug 19, 2026

Price to earnings forward of Phio Pharmaceuticals Corp. – BOATS:PHIO - TradingView

Aug 19, 2026

Aug 14, 2026

Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan

Aug 14, 2026

Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - Kalkine

Aug 14, 2026

Aug 13, 2026

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review

Aug 13, 2026

Aug 11, 2026

Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Nigeria

Aug 11, 2026

Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com

Aug 11, 2026

Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894 - Bitget

Aug 11, 2026

Phio Pharmaceuticals Receives U.S. Notice of Allowance for PH-894 Patent Targeting BRD4 Protein via INTASYL® Platform - kalkine.ca

Aug 11, 2026

Aug 10, 2026

Enterprise value to revenue forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView

Aug 10, 2026

Aug 08, 2026